Ellsworth Advisors LLC Raises Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Ellsworth Advisors LLC increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,962 shares of the specialty pharmaceutical company’s stock after purchasing an additional 149 shares during the period. Ellsworth Advisors LLC owned 0.06% of Jazz Pharmaceuticals worth $4,675,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 1.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 64,096 shares of the specialty pharmaceutical company’s stock valued at $6,841,000 after acquiring an additional 619 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Jazz Pharmaceuticals by 48.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock worth $130,447,000 after purchasing an additional 398,549 shares during the last quarter. Amalgamated Bank increased its position in Jazz Pharmaceuticals by 4.7% during the second quarter. Amalgamated Bank now owns 39,125 shares of the specialty pharmaceutical company’s stock worth $4,176,000 after purchasing an additional 1,745 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its stake in Jazz Pharmaceuticals by 51.7% during the second quarter. Mercer Global Advisors Inc. ADV now owns 3,485 shares of the specialty pharmaceutical company’s stock worth $372,000 after purchasing an additional 1,187 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Jazz Pharmaceuticals by 37.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,239 shares of the specialty pharmaceutical company’s stock valued at $664,000 after buying an additional 1,706 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on JAZZ shares. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,253 shares of company stock worth $1,001,434. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $121.18 on Monday. The firm has a market cap of $7.33 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 0.88 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business’s 50 day moving average is $122.78 and its two-hundred day moving average is $114.75. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.